Related Experiment Videos
Antithrombotic and thrombolytic therapies for acute myocardial infarction
S L Godfried1, J M Gaziano, C H Hennekens
1Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215-1204, USA.
Insights
Antithrombotic therapies like aspirin significantly reduce vascular death, reinfarction, and stroke in acute myocardial infarction (AMI) patients. While thrombolytic therapy also reduces mortality, wider and earlier use of these treatments could prevent numerous premature deaths globally.
Area of Science:
- Cardiology
- Thrombosis Research
- Pharmacology
Background:
- Acute myocardial infarction (AMI) treatment relies heavily on antithrombotic and thrombolytic therapies.
- Established benefits of aspirin in reducing vascular mortality, reinfarction, and stroke in AMI.
- Ongoing evaluation of additional antithrombotic agents and their net benefits in conjunction with aspirin.
Purpose of the Study:
- To review the established benefits of antithrombotic and thrombolytic therapies in acute myocardial infarction.
- To assess the evidence for additional antithrombotic agents (heparin, direct thrombin inhibitors) when combined with aspirin.
- To emphasize the importance of timely and widespread administration of available thrombolytic agents.
Main Methods:
- Review of existing clinical evidence and randomized trials on antithrombotic and thrombolytic therapies for AMI.
- Analysis of comparative efficacy and safety data for various treatment regimens.
- Evaluation of the potential impact of increased therapeutic utilization on public health outcomes.
Main Results:
- Aspirin as an antithrombotic agent provides conclusive vascular benefits for all suspected AMI patients.
- No clear net benefit demonstrated for adding heparin (delayed subcutaneous or immediate intravenous) to aspirin.
- Thrombolytic therapy significantly reduces mortality; early administration within 12 hours of symptom onset is recommended.
- Differences among thrombolytic agents are minor compared to the benefits of wider and earlier use.
Conclusions:
- Antithrombotic therapy with aspirin is crucial for all acute myocardial infarction patients.
- Further research is needed for direct thrombin inhibitors to confirm net benefits with aspirin.
- Widespread and earlier use of available thrombolytic agents can prevent substantial premature mortality worldwide.
Abstract:
Antithrombotic and thrombolytic therapies confer clear net benefits in the treatment of acute myocardial infarction. Antithrombotic therapy with aspirin yields conclusive reductions in vascular mortality as well as reinfarction and stroke, and should be administered to all patients with suspected acute myocardial infarction. There is presently no clear evidence of net benefits from adding either delayed subcutaneous or immediate intravenous heparin to an antithrombotic regimen of aspirin. Direct thrombin inhibitors have theoretical advantages over heparin as antithrombotic agents, but further data are needed from large-scale randomized trials to determine whether these agents confer net benefits when given in conjunction with aspirin. Thrombolytic therapy yields clear reductions in mortality and should be considered for all patients with suspected acute myocardial infarction presenting within 12 h of symptom onset. The differences in the efficacy, safety or ease of administration of the various thrombolytic agents are small compared with the substantial benefits that would result from the wider use and earlier administration of any of the available agents. More widespread use of antithrombotic and thrombolytic therapies for acute myocardial infarction could prevent tens of thousands of premature deaths annually in the USA alone, and hundreds of thousands worldwide.